Overall survival for patients with acute lymphoblastic leukemia.

At the time of analysis, 39 of the 48 ALL patients died, and 9 were censored for the analysis of overall survival: 5 discontinued therapy with imatinib to undergo BMT (3 subsequently died by the time of analysis); 1 was censored after 7 months after receiving interferon alfa; and 3 patients remained alive at the time of analysis, 9 to 12 months after starting treatment with imatinib (treatment is ongoing for only 1 of these 3 patients). The estimated median survival was 4.9 months with 95% CI = 4.1-7.1 months.